Qulipta (atogepant) was released on September 20, 2021 [1]. It is an oral medication approved for the preventive treatment of migraine [1].
What is Qulipta used for?
Qulipta is prescribed to prevent episodic migraines in adults [2]. It is not intended for the acute treatment of migraine attacks [2].
How does Qulipta work?
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. By blocking the action of CGRP, a molecule involved in migraine pain, the medication helps to prevent migraines from occurring [3].
Who makes Qulipta?
AbbVie manufactures and markets Qulipta [4].
What are the potential side effects of Qulipta?
Common side effects of Qulipta can include nausea, constipation, diarrhea, fatigue, and indigestion [2].
When does Qulipta's patent expire?
Patent information for Qulipta can be found on DrugPatentWatch.com [5]. Patent expiry dates are crucial for understanding when generic versions of a medication may become available.
What are the alternatives to Qulipta for migraine prevention?
Other preventive treatments for migraine include oral medications such as beta-blockers, antidepressants, and anticonvulsants, as well as CGRP-targeting monoclonal antibodies and onabotulinumtoxinA injections [3].
How does Qulipta compare to other CGRP inhibitors?
Qulipta is an oral CGRP receptor antagonist, differing from CGRP-targeting monoclonal antibodies (like Aimovig, Ajovy, Emgality, and Vyepti) which are administered via injection or infusion [3]. The choice between these treatments often depends on individual patient needs and preferences.
What clinical data supports Qulipta's effectiveness?
Clinical trials for Qulipta demonstrated a significant reduction in monthly migraine days compared to placebo in patients with episodic migraine [1]. Specific data on efficacy and safety from these trials are available in prescribing information.
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-qulipta-atogepant-preventive-treatment-migraine
[2] https://www.qulipta.com/
[3] https://migraine.com/treatment/preventive/cgrps/
[4] https://www.abbvie.com/our-science/pipeline/approved-products.html
[5] https://drugpatentwatch.com/